GVFL led the Rs. 4 crore seed funding round in Vadodara-based Genexis Biotech, a next-generation bio-manufacturing company focused on animal-origin-free recombinant proteins. Benzai10 also participated in the funding round.
Genexis Biotech will utilise the capital to expand its bioreactor capacity, build downstream processing infrastructure, and launch a new line of smart proteins and recombinant peptidase enzymes. It will also use the funds to strengthen quality control, regulatory compliance, and expand its sales and distribution channels.
Speaking on the investment, Mihir Joshi, Managing Director of GVFL, said, “Genexis is solving a critical gap in India’s biotech value chain by enabling high-quality, animal-origin-free protein production at scale. The company’s R&D strength, infrastructure, and early traction position it well to serve a growing demand across biopharma, food-tech, and life sciences. We are pleased to support Genexis in this transformative journey.”
In the past 12 months, Genexis has developed a range of recombinant growth factors, peptidases, and cell culture reagents. It has established strategic partnerships with pharmaceutical companies, biotech startups, and research laboratories. The company’s certified Class 10,000 manufacturing facility is now operational, with plans underway for a GMP-compliant unit.
Vipul Kumar, Director at Genexis Biotech, said, “At Genexis Biotech, we are building India’s deep-tech backbone for animal-origin-free protein production. The seed round marks a key milestone in our journey and will accelerate our path to scale, enabling sustainable innovation across healthcare, food, and bio-industrial sectors.”
Genexis Biotech recently introduced recombinant peptidases such as amino peptidase and enterokinase, and is preparing to launch recombinant transferrin and albumin. Genexis also signed an MoU with the Gujarat government for scaling up recombinant protein manufacturing and showcased its portfolio at Global Bio-India 2024. It has secured multiple clients and has received orders for alternative protein formulation projects.
In the next phase of growth, Genexis Biotech aims to enter the regulated biotech export market, form strategic collaborations with Contract Development and Manufacturing Organisations (CDMOs), academic labs and biopharma companies. Its plans also include developing encapsulated growth factor formulations for the cosmetics industry.
𝐒𝐭𝐚𝐲 𝐢𝐧𝐟𝐨𝐫𝐦𝐞𝐝 𝐰𝐢𝐭𝐡 𝐨𝐮𝐫 𝐥𝐚𝐭𝐞𝐬𝐭 𝐮𝐩𝐝𝐚𝐭𝐞𝐬 𝐛𝐲 𝐣𝐨𝐢𝐧𝐢𝐧𝐠 𝐭𝐡𝐞 WhatsApp Channel now! 👈📲
𝑭𝒐𝒍𝒍𝒐𝒘 𝑶𝒖𝒓 𝑺𝒐𝒄𝒊𝒂𝒍 𝑴𝒆𝒅𝒊𝒂 𝑷𝒂𝒈𝒆𝐬 👉 Facebook, LinkedIn, Twitter, Instagram
